Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 56 | ECE2018 | Next issue

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

Card image cap
ECE 2018, 19 - 22 May 2018; Barcelona, Spain

Guided Posters

Thyroid non cancer - Benign Thyroid disease/ treatment

ea0056gp265 | Thyroid non cancer - Benign Thyroid disease/ treatment | ECE2018

Nodule size as predictive factor of efficacy of radiofrequency ablation in treating autonomously functioning thyroid nodules

Palermo Andrea , Naciu Anda Mihaela , Iozzino Mario , Pasqualini Valerio , Simeoni Carla , Manfrini Silvia , Tabacco Gaia , Casini Alessandro , Campagna Giuseppe , Cesareo Roberto

Background: Radiofrequency ablation(RFA) has been advocated as an alternative to radioiodine and/or surgery for the treatment of autonomously functioning benign thyroid nodule (AFTN). However, only a few studies have investigated the efficacy of RFA on AFTN. Furthermore, these studies are characterized by several biases about patient selection, number of RFA treatments, short clinical and radiographic follow-up. A recent prospective 12-month study has demonstrated that one sin...

ea0056gp266 | Thyroid non cancer - Benign Thyroid disease/ treatment | ECE2018

Radiofrequency ablation for benign symptomatic thyroid nodules: evaluation of clinical efficacy

Vozdvizhenskii Mikhail , Orlov Andrey , Makhonin Aleksandr , Stadler Vladimir , Matyash Yana

Purpose: Thyroid nodules are an extremely common occurrence. The aim of the study is to evaluate the results of radiofrequency ablation (RFA) for benign symptomatic thyroid nodules.Materials and methods: Three hundred and sixty two patients with benign symptomatic thyroid nodules (TIRADS/ Bethesda: TIRADS 2, TIRADS 3/THY 2) were included in this research: 355 women and 7 men. The median age of the group was 48 (24–76). The mean nodule size was 3.5 (...

ea0056gp268 | Thyroid non cancer - Benign Thyroid disease/ treatment | ECE2018

Response to Liothyronine therapy: Efficiacy of therapy and assessment of biochemical and physiological predictors

Philbey Christopher , Malik Mohammed

Introduction: Levothyroxine is the globally preferred therapeutic compound for primary hypothyroidism. Due to expense and poor efficacy, Liothyronine is not used as first line treatment. This study was formed to answer the ESE’s recent call for data on symptomatic response to Liothyronine and predictors of that response.Method: Patients with failure of symptomatic relief on levothyroxine were invited to try Liothyronine. 23 patients were enrolled. T...

ea0056gp269 | Thyroid non cancer - Benign Thyroid disease/ treatment | ECE2018

Tailored thyroxine treatment and gastric acid output in humans

Virili Camilla , Bruno Giovanni , Santaguida Maria Giulia , Porowska Barbara , Capriello Silvia , De Vito Corrado , Severi Carola , Centanni Marco

Hypothyroid patients with gastric disorders require a higher dose of oral thyroxine (T4) to reach target serum TSH. In vitro evidence supports the notion that the variations of gastric pH may also interfere with T4 dissolution profile. The present study is aimed at confirming in vivo the supposed correlation between the gastric pH, directly measured during endoscopy, and the therapeutic dose of thyroxine using a controlled treatment schedule. A total of 61 tablet T4-t...

ea0056gp270 | Thyroid non cancer - Benign Thyroid disease/ treatment | ECE2018

Body composition changes during treatment of severe thyroid disorders. Is it always fat?

Zybek-Kocik Ariadna , Sawicka-Gutaj Nadia , Szczepanek-Parulska Ewelina , Krauze Tomasz , Guzik Przemyslaw , Ruchala Marek

Severe thyroid disorder are associated with important metabolic changes. After restoration of euthyroidism, as a result of proper treatment, usually body metabolism also normalizes. Up to date, there are conflicting reports about the changes in body composition of patients during treatment of severe hyperthyroidism and hypothyroidism. The aim of this study was to evaluate the body composition and glucose level changes in subjects affected by Graves disease and autoimmune thyro...

ea0056gp271 | Thyroid non cancer - Benign Thyroid disease/ treatment | ECE2018

Personalised euthyroid targets based on a deterministic mathematical model

Li Enlin , Leow Melvin Khee-Shing

Research in recent years has shown that biochemically euthyroid levels of thyrotropin (TSH) and serum free thyroxine (FT4) as determined by laboratories may not necessarily equate to clinical well-being of patients. The defined normal range of TSH and FT4 are wide and may differ from patients’ optimal range of TSH and FT4. We have previously described a deterministic mathematical model that can predict each patient’s unique homeostatic set point, which gives the opti...

ea0056gp272 | Thyroid non cancer - Benign Thyroid disease/ treatment | ECE2018

US-guided percutaneous microwave ablation for benign thyroid nodules: a prospective multicenter study

Liang Ping

Purpose: To evaluate the clinical outcomes of percutaneous MWA in treating BTNs under US guidance with a prospective multicenter study.Materials and methods: From January of 2013 to December of 2015, the total number of 603 patients with 664 benign thyroid nodules (BTNs) at four participating institutions in China was enrolled in the multicenter study. Before ablation, the mean maximal diameter and the mean volume of the target nodules were 2.92±0.9...

ea0056gp274 | Thyroid non cancer - Benign Thyroid disease/ treatment | ECE2018

Reduced quality of life and persistent complaints in treated hypothyroid patients

Molewijk Ellen , Martens Maayan , Fliers Eric , Zelissen Pierre , Dreijerink Koen , van Dooren Ad , Heerdink Rob

Background: Hypothyroidism is a common endocrine disorder and the standard treatment is replacement therapy with levothyroxine (LT4). Although many hypothyroid patients improve upon treatment with LT4, a proportion seems to experience residual hypothyroid complaints despite treatment, even when plasma TSH and FT4 are within reference ranges.Methods: Using an on-line survey we investigated i) the health-related quality of life (QoL) (ThyPRO), ii) the acti...